TRT vs supraphysiologic testosterone: what the science says

What did @drvictorchan actually say?

Dr. Chan made two core claims: first, that TRT's purpose is to "restore natural levels when the body's production decreases," and second, that superphysiologic doses, meaning amounts exceeding those natural levels, "create a completely different biological situation" by pushing the body "outside of its natural regulatory systems." He also flagged a pattern he noticed in his own comment section where people suggested that going well above the reference range would feel even better than optimizing within it.

This is a reasonable, clinically grounded framing. He did not prescribe specific doses, did not recommend supraphysiologic use, and actively pushed back on the idea that higher is always better. That is worth noting, because a lot of TRT content on TikTok goes the other direction.

Does the science back this up?

Yes, on the fundamentals, the research is solidly on his side. The distinction between replacement-level and supraphysiologic testosterone is well-established in endocrinology literature, and the physiological consequences of exceeding normal ranges are not trivial.

The Endocrine Society's clinical practice guidelines define hypogonadism as total testosterone below approximately 300 ng/dL in men with consistent symptoms, and the treatment goal is restoration to the mid-normal range, not the ceiling of it (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). What happens beyond that range is a different story. Supraphysiologic testosterone reliably suppresses endogenous production via negative feedback on the hypothalamic-pituitary-gonadal axis, elevates hematocrit, increases cardiovascular strain, and can suppress spermatogenesis. A landmark controlled trial by Bhasin et al. (1996, New England Journal of Medicine) demonstrated that exogenous testosterone at supraphysiologic doses produced significant muscle and strength gains, but the safety profile of long-term use at those levels in non-research settings is not well characterized.

The comment-section dynamic Dr. Chan described, where users escalate dose recommendations beyond reference ranges, is a real phenomenon with real clinical consequences.

What did they get wrong (or right)?

Mostly right, with one gap worth mentioning. Dr. Chan correctly identifies that supraphysiologic doses operate outside normal regulatory systems, which is accurate physiology. He is also right to treat the comment-section advice as something worth publicly correcting.

The gap is that he does not define what "natural levels" or the "normal reference range" actually means in clinical practice, which matters more than it sounds. Reference ranges for total testosterone vary across labs, are population-derived, and may not reflect optimal function for any individual patient. The American Urological Association and the Endocrine Society use different thresholds. Treating the reference range as a fixed, universal ceiling oversimplifies the clinical picture. Some men with low-normal testosterone still have symptomatic hypogonadism; others at the same level do not. Symptom correlation matters as much as the number.

He also does not distinguish between total and free testosterone, which is a meaningful omission for anyone trying to understand why two people with the same total level can feel completely different. That said, this is a short TikTok clip, not a clinical lecture, so the omission is forgivable given context.

What should you actually know?

The core message here is defensible and worth internalizing: TRT dosed to restore normal physiologic levels and supraphysiologic testosterone use are not the same thing, and should not be evaluated by the same risk-benefit framework.

Approved TRT protocols, whether testosterone cypionate, enanthate, gels, or patches, are designed to bring deficient men back into a normal range, not to push anyone above it. The risks associated with supraphysiologic use, including erythrocytosis, cardiovascular strain, liver stress with certain oral forms, and HPG axis suppression, are dose-dependent. They are not an argument against appropriately dosed TRT for diagnosed hypogonadism; they are an argument against chasing an artificially elevated number.

If you are on TRT and wondering whether more would be better, the honest answer from the literature is: probably not for longevity, and potentially harmful for cardiovascular health. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found that testosterone therapy in middle-aged and older men with hypogonadism did not significantly increase major cardiovascular events at therapeutic doses, but this was not a study of supraphysiologic dosing.

• Work with a clinician who monitors hematocrit, PSA, and lipids, not just total testosterone.
• "Feeling better" at a higher level does not make that level safe long-term.
• Reference ranges are population averages, not personal targets. Symptom assessment matters.